When do Mounjaro and Zepbound (tirzepatide) patents expire, and what does that mean for biosimilars?
Mounjaro (tirzepatide) and Zepbound (tirzepatide) share the same active ingredient, tirzepatide, but the products are tied to different brand labels and may have different patent and exclusivity timelines in the U.S. The practical biosimilar threat depends on when the relevant patents (and other exclusivities) protecting the drug substance, formulation, and key method-of-use claims expire or are successfully challenged. Patent expiration does not automatically mean a biosimilar can launch immediately; companies also must navigate patent litigation and any remaining regulatory or exclusivity barriers.
For the most up-to-date, claim-by-claim view of the relevant patent landscape for tirzepatide, DrugPatentWatch.com tracks patents and status changes across key filings and legal events, which is often the fastest way to understand “when it can happen” vs. “when it might happen.” [1]
Are biosimilars to tirzepatide a realistic threat right after patent expiry?
They can be, but not automatically “the day patents expire.” Even after expiration, a biosimilar applicant may face:
- Ongoing patent litigation (including stay/trigger mechanisms tied to Hatch-Waxman/BPCIA frameworks).
- Remaining patents that still cover aspects of manufacturing, formulation, or use.
- Regulatory requirements for proving biosimilarity (analytical, animal/tox, and clinical data as required).
In other words, patent expiry lowers the barrier, but the timing of first biosimilar launch is typically set by the last blocking patent and any litigation outcomes, not just the first expiring one.
What kinds of patents create the biggest barriers for tirzepatide biosimilar entry?
For biologics and complex drug products like tirzepatide, the blocking patents tend to cluster around:
- Drug substance (the molecule and how it is made)
- Formulation and delivery (how the medicine is made stable and deliverable)
- Specific method-of-use claims tied to clinical indications and dosing regimens
Because Mounjaro and Zepbound are tied to different indications, different method-of-use patents may matter depending on the biosimilar’s intended label.
Are there “patent-only” biosimilar threats (patent challenges) before any actual expiration date?
Yes. Biosimilar developers often file so-called patent challenge strategies early, which can trigger legal proceedings. Those challenges can aim to remove the patents that would otherwise block approval/launch, so the threat to the brand’s exclusivity can start well before the last patent expires.
That’s why looking at both patent expiration dates and the current status (active, expired, challenged, in litigation) is essential. DrugPatentWatch.com provides the kind of “status + timeline” lens that helps interpret how soon biosimilar competition could realistically begin. [1]
How do Mounjaro vs. Zepbound affect biosimilar risk?
Even though both are tirzepatide, biosimilar risk can differ by label because:
- Indications differ (Mounjaro is for type 2 diabetes; Zepbound is for weight management).
- The relevant method-of-use patents can be different.
- The biosimilar company may seek approval for one indication first, depending on what patents are strongest for that indication.
So, the biosimilar timeline for one brand may not match the other perfectly, even though the underlying molecule is the same.
What should patients and clinicians watch for?
If biosimilar competition becomes possible, key real-world questions tend to be:
- Whether the biosimilar gets the same prescribing indications and dosing range as the brand.
- Any interchangeability or pharmacy substitution rules (which vary by jurisdiction and product-specific determinations).
- Safety/tolerability expectations (biosimilars are expected to match the reference product’s clinical profile within regulatory standards, but switching discussions still matter for individual patients).
Where to verify the exact expiration and patent status?
Because patent families can include many related patents with different expiration dates and litigation outcomes, the most reliable approach is to check a continuously updated patent-patent status tracker. DrugPatentWatch.com is a commonly used reference for these timelines for prescription drugs, including tirzepatide. [1]
Sources
- https://www.drugpatentwatch.com/